Literature DB >> 8627081

The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1-65 years.

L A Cattaneo1, G W Reed, D H Haase, M J Wills, K M Edwards.   

Abstract

Although the incidence of Bordetella pertussis infections had decreased significantly since the introduction of widespread vaccination, an increase in the number of cases has occurred recently. In an attempt to define the seroepidemiology of pertussis in Nashville, antibody levels to pertussis toxin (PT) and filamentous hemagglutinin (FHA) were measured by ELISA in 585 serum samples from healthy 1- to 65-year-old subjects. Data were analyzed by smooth curve fitting and by comparison of trends in PT and FHA titers across age groups. The results demonstrated a peak in PT and FHA titers in the 4-6 year age group, concurrent with the administration of booster doses of diphtheria-tetanus toxoid-pertussis vaccine. A second larger peak was noted in the 13-17 year age group. These data suggest that pertussis infection is frequent during the adolescent years.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627081     DOI: 10.1093/infdis/173.5.1256

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis.

Authors:  H E de Melker; F G Versteegh; M A Conyn-Van Spaendonck; L H Elvers; G A Berbers; A van Der Zee; J F Schellekens
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Sero epidemiology of Bordetella pertussis immune responses in a healthy population in northern Greece.

Authors:  A Polyzou; S Pournaras; U Dafni; D Sofianou; E Christeli; S Patrinos; A Tsakris
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

3.  Bordetella pertussis IgG and IgA antibodies seroprevalence among 1-35 y-old population: the role of subclinical pertussis infection.

Authors:  Mohammed-Jafar Saffar; Ali-Reza Khalilian; Ali-Reza Rafee; Mohammed Reza Parsaei; Shadi Imanikhani; Jalil Shojaei; Hana Saffar
Journal:  Indian J Pediatr       Date:  2011-11-22       Impact factor: 1.967

4.  Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States.

Authors:  Andrew L Baughman; Kristine M Bisgard; Kathryn M Edwards; Dalya Guris; Michael D Decker; Kathy Holland; Bruce D Meade; Freyja Lynn
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

5.  Natural immune boosting in pertussis dynamics and the potential for long-term vaccine failure.

Authors:  Jennie S Lavine; Aaron A King; Ottar N Bjørnstad
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-21       Impact factor: 11.205

Review 6.  An overview of the status of acellular pertussis vaccines in practice.

Authors:  A L Lopez; D A Blumberg
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 7.  Laboratory diagnosis of pertussis: state of the art in 1997.

Authors:  F M Müller; J E Hoppe; C H Wirsing von König
Journal:  J Clin Microbiol       Date:  1997-10       Impact factor: 5.948

8.  The seroepidemiology of pertussis in Australia during an epidemic period.

Authors:  M Cagney; C R MacIntyre; P McIntyre; M Puech; A Giammanco
Journal:  Epidemiol Infect       Date:  2006-05-11       Impact factor: 2.451

9.  Seroprevalence of Immunoglobulin G antibodies against pertussis toxin among asymptomatic medical students in the west of Iran: a cross sectional study.

Authors:  Seyyed Hamid Hashemi; Mitra Ranjbar; Mehrdad Hajilooi; Mohammad-Ali Seif-Rabiei; Mahnaz Bolandi; Javad Moghimi
Journal:  BMC Infect Dis       Date:  2009-05-09       Impact factor: 3.090

10.  Infantile pertussis rediscovered in China.

Authors:  Jingmin Wang; Yonghong Yang; Jie Li; Jussi Mertsola; Heikki Arvilommi; Xuzhuang Shen; Qiushui He
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.